BGIM
HZNP

Boussard & Gavaudan Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-696,259
Closed -$80.5M – 111
2023
Q3 		$80.5M Sell
696,259
-25,577
-4% -$2.75M 9.41% 2
2023
Q2 		$74.4M Buy
721,836
+158,130
+28% +$16.7M 7.07% 1
2023
Q1 		$61.4M Buy
+563,706
New +$62.3M 5.78% 2

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Boussard & Gavaudan Investment Management's HZNP Position: Q4 2023 in Review

Boussard & Gavaudan Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 696,259 shares — an estimated $80.5M sold.

Boussard & Gavaudan Investment Management first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $80.5M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Boussard & Gavaudan Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 696,259 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $80.5M.
  • Boussard & Gavaudan Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Boussard & Gavaudan Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $80.5M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q4 2023, filed 13 Feb 2024.